PALO ALTO, Calif., September 6, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the BioCentury 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 3:30 pm ET at the Millennium Broadway Hotel & Conference Center in New York City.
A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
SOURCE Eiger Bio, Inc.
Investors: Jim Shaffer, Eiger Bio, Inc., 919-345-4256, email@example.com